Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855880 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
A Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by AbGenomics B.V Taiwan Branch.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 15
- Study locations
NCT01855880 is a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis that has completed, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 54 participants, below the 210-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 9 states.
The verdict
NCT01855880, a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, has completed, sponsored by AbGenomics B.V Taiwan Branch.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of AbGn-168H administered intravenously to patients with moderate to severe chronic plaque psoriasis.
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL AbGn-168H
Study Locations (15)
Florida
- Visions Clinical Research - Boynton Beach
- Renstar Medical Research - Ocala
- Progressive Medical Research - Orange
- Olympian Clinical Research - Tampa
Arkansas
- Baptist Health Certer for Clinical Research - Little Rock
- Northwest AR Clinical Trials - Rogers
Indiana
- DawesFretzin Clinical Research Group, LLC. - Indianaopoli
- Indiana University Dermatology - Indianapolis
New York
- University Urology Associates & Manhattan Research Associates - New York
- Mount Sinai School of Medicine - New York
New Jersey
- Comprehensive Clinical Research - Berlin
Oklahoma
- Research Affiliation - Oklahoma City
South Carolina
- Radiant Research, Inc. - Greer
Texas
- Suzanne Bruce and Associates, The Center for Skin Research - Huston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855880
The ClinicalTrials.gov registry entry for NCT01855880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (74% lower). The listed sponsor is AbGenomics B.V Taiwan Branch, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate-to-severe Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01855880 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arkansas, Indiana.
Frequently Asked Questions
What is clinical trial NCT01855880 about?
NCT01855880 is a clinical study titled "Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients". This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of...
What is the current status of trial NCT01855880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2013-05. Estimated completion is 2014-03.
What conditions does trial NCT01855880 study?
This clinical trial studies the following conditions: Moderate-to-severe Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT01855880?
The interventions under investigation include: placebo (BIOLOGICAL), AbGn-168H (BIOLOGICAL).
Who is sponsoring clinical trial NCT01855880?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01855880 being conducted?
This trial has 15 study locations across Arkansas, Florida, Indiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-severe Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.